ARL4A

Summary

ARL4A (ARF like GTPase 4A, HGNC:695) is a protein-coding gene on chromosome 7p21.3, encoding ADP-ribosylation factor-like protein 4A (P40617). Small GTP-binding protein which cycles between an inactive GDP-bound and an active GTP-bound form, and the rate of cycling is regulated by guanine nucleotide exchange factors (GEF) and GTPase-activating proteins (GAP).

ADP-ribosylation factor-like 4A is a member of the ADP-ribosylation factor family of GTP-binding proteins. ARL4A is similar to ARL4C and ARL4D and each has a nuclear localization signal and an unusually high guaninine nucleotide exchange rate. ARL4A is located in both the nuclear and extranuclear cell compartments. Multiple transcript variants encoding the same protein have been found for this gene.

Source: NCBI Gene 10124 — RefSeq curated summary.

At a glance

• GWAS associations: 6
• Clinical variants (ClinVar): 30 total
• MANE Select transcript: NM_005738

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:695
Approved symbol	ARL4A
Name	ARF like GTPase 4A
Location	7p21.3
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000122644
Ensembl biotype	protein_coding
OMIM	604786
Entrez	10124

Gene structure

Transcript identifiers

Ensembl transcripts: 12 — 12 protein_coding

ENST00000356797, ENST00000396662, ENST00000396663, ENST00000396664, ENST00000404894, ENST00000439721, ENST00000651779, ENST00000891906, ENST00000931767, ENST00000931768, ENST00000931769, ENST00000931770

RefSeq mRNA: 4 — MANE Select: NM_005738 NM_001037164, NM_001195396, NM_005738, NM_212460

CCDS: CCDS5359

Canonical transcript exons

ENST00000651779 — 2 exons

Exon	Start	End
ENSE00003842422	12687633	12687728
ENSE00003848207	12688166	12690958

Expression profiles

Bgee: expression breadth ubiquitous, 136 present calls, max score 98.72.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 30.1052 / max 1751.5879, expressed in 1764 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
77291	21.6933	1637
77288	7.9926	1619
77289	0.2262	76
77290	0.1385	47
77287	0.0545	12

Top tissues by expression

138 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
left testis	UBERON:0004533	98.72	gold quality
right testis	UBERON:0004534	98.47	gold quality
testis	UBERON:0000473	97.83	gold quality
skin of abdomen	UBERON:0001416	95.81	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	95.53	gold quality
mucosa of transverse colon	UBERON:0004991	95.38	gold quality
zone of skin	UBERON:0000014	95.19	gold quality
skin of leg	UBERON:0001511	94.68	gold quality
lower esophagus mucosa	UBERON:0035834	94.30	gold quality
vagina	UBERON:0000996	94.14	gold quality
esophagus mucosa	UBERON:0002469	94.02	gold quality
calcaneal tendon	UBERON:0003701	93.29	gold quality
rectum	UBERON:0001052	93.23	gold quality
small intestine Peyer’s patch	UBERON:0003454	92.46	gold quality
transverse colon	UBERON:0001157	92.34	gold quality
small intestine	UBERON:0002108	92.21	gold quality
bone marrow	UBERON:0002371	92.19	gold quality
esophagus	UBERON:0001043	92.00	gold quality
smooth muscle tissue	UBERON:0001135	91.71	gold quality
thoracic mammary gland	UBERON:0005200	91.66	gold quality
ectocervix	UBERON:0012249	91.65	gold quality
duodenum	UBERON:0002114	91.40	gold quality
intestine	UBERON:0000160	91.17	gold quality
monocyte	CL:0000576	91.02	gold quality
tonsil	UBERON:0002372	90.74	gold quality
colon	UBERON:0001155	90.70	gold quality
leukocyte	CL:0000738	90.46	gold quality
omental fat pad	UBERON:0010414	90.32	gold quality
adipose tissue	UBERON:0001013	90.17	gold quality
subcutaneous adipose tissue	UBERON:0002190	90.06	gold quality

Single-cell (SCXA)

Detected in 15 experiment(s), a significant marker in 12.

Experiment	Marker?	Max mean expression
E-MTAB-9841	yes	1334.51
E-CURD-98	yes	1210.25
E-MTAB-10855	yes	1106.02
E-MTAB-10885	yes	900.11
E-MTAB-8142	yes	96.68
E-MTAB-10287	yes	67.14
E-HCAD-1	yes	23.40
E-MTAB-8410	yes	23.31
E-GEOD-135922	yes	12.68
E-CURD-46	yes	10.56
E-CURD-114	yes	9.79
E-MTAB-10042	no	470.28
E-MTAB-6108	no	363.77
E-HCAD-5	no	2.25
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): CTNNB1

miRNA regulators (miRDB)

109 targeting ARL4A, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-188-3P	100.00	68.76	1240
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-6759-5P	99.99	66.54	785
HSA-MIR-4482-3P	99.98	72.50	3147
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-3065-5P	99.97	71.56	3281
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-7152-3P	99.97	67.47	849
HSA-MIR-551B-5P	99.96	71.28	3493
HSA-MIR-1250-3P	99.96	70.04	4038
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-9-3P	99.96	70.88	2068
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-545-3P	99.95	70.74	2783
HSA-MIR-3912-5P	99.95	66.11	925
HSA-MIR-141-3P	99.94	72.79	2421
HSA-MIR-200A-3P	99.94	72.68	2420
HSA-MIR-548J-3P	99.94	72.61	4881
HSA-MIR-335-3P	99.93	73.36	4958
HSA-MIR-3143	99.93	71.96	3104
HSA-MIR-548AE-3P	99.93	72.66	4867
HSA-MIR-548AH-3P	99.93	72.54	4872
HSA-MIR-548AM-3P	99.93	72.54	4872

Literature-anchored findings (GeneRIF, showing 6)

• Study shows that three related Arf-like GTPases Arl4a, Arl4c, and Arl4d, are able to recruit ARNO and other cytohesins to the plasma membrane by binding to their PH domains irrespective of whether they are in the diglycine or triglycine form. (PMID:17398095)
• The loss of PTEN was shown to lead to increased levels of ARF4L protein but no change in transcript levels. The ARF4L transcript preferentially localized to the polysomal compartment after PTEN loss in glioma. (PMID:18240926)
• membrane targeting of ELMO via Arl4A promotes cytoskeletal reorganization including membrane ruffling and stress fiber disassembly via an ELMO-DOCK1800-Rac signaling pathway. (PMID:21930703)
• Deletion of the ARL4A-interacting region of GCC185 results in inability to maintain Golgi structure and modulate endosome-to-Golgi transport. (PMID:22159419)
• Arl4A participates in Slit2/Robo1 signaling to modulate cell motility by regulating Cdc42 activity. (PMID:30427759)
• Phosphorylation of Arl4A/D promotes their binding by the HYPK chaperone for their stable recruitment to the plasma membrane. (PMID:35857868)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	arl4aa	ENSDARG00000099918
mus_musculus	Arl4a	ENSMUSG00000047446
rattus_norvegicus	Arl4a	ENSRNOG00000069300

Paralogs (30): ARF5 (ENSG00000004059), SAR1A (ENSG00000079332), ARFRP1 (ENSG00000101246), TRIM23 (ENSG00000113595), ARL6 (ENSG00000113966), ARL1 (ENSG00000120805), ARL8B (ENSG00000134108), ARF3 (ENSG00000134287), ARL3 (ENSG00000138175), ARL5C (ENSG00000141748), ARF1 (ENSG00000143761), ARL8A (ENSG00000143862), ARL11 (ENSG00000152213), SAR1B (ENSG00000152700), ARL5A (ENSG00000162980), ARF6 (ENSG00000165527), ARL5B (ENSG00000165997), ARF4 (ENSG00000168374), ARL13B (ENSG00000169379), ARL13A (ENSG00000174225), ARL10 (ENSG00000175414), ARL4D (ENSG00000175906), ARL14 (ENSG00000179674), ARL15 (ENSG00000185305), ARL17A (ENSG00000185829), ARL4C (ENSG00000188042), ARL9 (ENSG00000196503), ARL2 (ENSG00000213465), ARL16 (ENSG00000214087), ARL17B (ENSG00000228696)

Protein

Protein identifiers

ADP-ribosylation factor-like protein 4A — P40617 (reviewed: P40617)

All UniProt accessions (2): C9J7Q9, P40617

UniProt curated annotations — full annotation on UniProt →

Function. Small GTP-binding protein which cycles between an inactive GDP-bound and an active GTP-bound form, and the rate of cycling is regulated by guanine nucleotide exchange factors (GEF) and GTPase-activating proteins (GAP). GTP-binding protein that does not act as an allosteric activator of the cholera toxin catalytic subunit. Recruits CYTH1, CYTH2, CYTH3 and CYTH4 to the plasma membrane in GDP-bound form.

Subunit / interactions. Interacts with CYTH2. Interacts with KPNA2; the interaction is direct. Does not interact with ARL4A.

Subcellular location. Cell membrane. Cytoplasm. Nucleus. Nucleolus.

Post-translational modifications. Myristoylated.

Similarity. Belongs to the small GTPase superfamily. Arf family.

RefSeq proteins (4): NP_001032241, NP_001182325, NP_005729, NP_997625 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR005225	Small_GTP-bd	Domain
IPR006689	Small_GTPase_ARF/SAR	Family
IPR024156	Small_GTPase_ARF	Family
IPR027417	P-loop_NTPase	Homologous_superfamily

Pfam: PF00025

UniProt features (8 total): binding site 3, mutagenesis site 2, initiator methionine 1, chain 1, lipid moiety-binding region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P40617-F1	91.87	0.85

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (3): 27–34; 75–79; 134–137

Post-translational modifications (1): 2

Mutagenesis-validated functional residues (2):

Position	Phenotype
34	inhibits relocalization of cyth2 to the plasma membrane. strongly localized in the nucleolus.
79	localized in the nucleus and nucleolus.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 363 (showing top): RNGTGGGC_UNKNOWN, TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_MONOCYTE_UP, GOBP_INTRACELLULAR_PROTEIN_TRANSPORT, YAO_HOXA10_TARGETS_VIA_PROGESTERONE_UP, BECKER_TAMOXIFEN_RESISTANCE_UP, TTTGTAG_MIR520D, GOZGIT_ESR1_TARGETS_DN, HALMOS_CEBPA_TARGETS_UP, MCBRYAN_PUBERTAL_TGFB1_TARGETS_UP, BROWNE_HCMV_INFECTION_16HR_UP, KANNAN_TP53_TARGETS_DN, GOBP_VESICLE_MEDIATED_TRANSPORT, TAL1ALPHAE47_01, CTATGCA_MIR153, EFC_Q6

GO Biological Process (3): intracellular protein transport (GO:0006886), vesicle-mediated transport (GO:0016192), brown fat cell differentiation (GO:0050873)

GO Molecular Function (4): GTPase activity (GO:0003924), GTP binding (GO:0005525), nucleotide binding (GO:0000166), protein binding (GO:0005515)

GO Cellular Component (7): nucleus (GO:0005634), nucleoplasm (GO:0005654), nucleolus (GO:0005730), cytoplasm (GO:0005737), cytosol (GO:0005829), plasma membrane (GO:0005886), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	4
nuclear lumen	2
intracellular protein localization	1
protein transport	1
intracellular transport	1
transport	1
cellular process	1
fat cell differentiation	1
ribonucleoside triphosphate phosphatase activity	1
guanyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
binding	1
intracellular membrane-bounded organelle	1
intracellular membraneless organelle	1
intracellular anatomical structure	1
cytoplasm	1
membrane	1
cell periphery	1

Protein interactions and networks

STRING

1769 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ARL4A	CYTH2	Q99418	822
ARL4A	GCC2	Q8IWJ2	740
ARL4A	CYTH3	O43739	718
ARL4A	SOS2	Q07890	685
ARL4A	ELMO1	Q92556	677
ARL4A	CDKN2A	P42771	657
ARL4A	CYTH4	Q9UIA0	643
ARL4A	KPNA2	P52292	623
ARL4A	CYTH1	Q15438	611
ARL4A	LAMB1	P07942	596
ARL4A	FHOD1	Q9Y613	507
ARL4A	ARL16	Q0P5N6	507
ARL4A	GOLGA2	Q08379	491
ARL4A	JDP2	Q8WYK2	477
ARL4A	SUMF2	Q8NBJ7	441

IntAct

30 interactions, top by confidence:

A	B	Type	Score
ARL4A	GOLGA2	psi-mi:“MI:0915”(physical association)	0.720
GOLGA2	ARL4A	psi-mi:“MI:0915”(physical association)	0.720
ARL4A	CCDC102B	psi-mi:“MI:0915”(physical association)	0.560
ARL4A	CCDC57	psi-mi:“MI:0915”(physical association)	0.560
ARL4A	SPATC1L	psi-mi:“MI:0915”(physical association)	0.560
CCDC57	ARL4A	psi-mi:“MI:0915”(physical association)	0.560
SPATC1L	ARL4A	psi-mi:“MI:0915”(physical association)	0.560
KRT19	ARL4A	psi-mi:“MI:0915”(physical association)	0.560
ARL4A	MTUS2	psi-mi:“MI:0915”(physical association)	0.560
ARL4A	POF1B	psi-mi:“MI:0915”(physical association)	0.560
EVI5	ARL4A	psi-mi:“MI:0915”(physical association)	0.560
FCN1	ARL4A	psi-mi:“MI:0915”(physical association)	0.370
ARL4A	KRT19	psi-mi:“MI:0915”(physical association)	0.000
ARL4A	EVI5	psi-mi:“MI:0915”(physical association)	0.000
ARL4A	MTUS2	psi-mi:“MI:0915”(physical association)	0.000
ARL4A	POF1B	psi-mi:“MI:0915”(physical association)	0.000
ARL4A	GOLGA2	psi-mi:“MI:0915”(physical association)	0.000
ARL4A		psi-mi:“MI:0915”(physical association)	0.000

BioGRID (22): ARL4A (Two-hybrid), CCDC102B (Two-hybrid), SPATC1L (Two-hybrid), CCDC57 (Two-hybrid), ARL4A (Synthetic Lethality), ARL4A (Two-hybrid), ARL4A (Affinity Capture-Western), ARL4A (Affinity Capture-Western), ARL4A (Affinity Capture-Western), ELMO1 (Co-localization), RAC1 (Co-localization), ARL4A (Affinity Capture-Western), ARL4A (Two-hybrid), GCC2 (Two-hybrid), GCC2 (Affinity Capture-Western)

ESM2 similar proteins: A8ISN6, B5FYQ0, F4IZ82, O00909, O14966, O45379, P11076, P25160, P36405, P37996, P38116, P40616, P40617, P40940, P49702, P51646, P56559, P61208, P61211, P61212, P61213, P61214, Q13795, Q19705, Q1MTE5, Q2KJ96, Q2TBW6, Q2YDM1, Q32LJ2, Q3T0M9, Q52NJ4, Q54R04, Q54UF1, Q5R579, Q5R7A4, Q5RCQ6, Q627K4, Q63055, Q80ZU0, Q8BXL7

Diamond homologs: O00909, O08697, O23778, O48649, O48920, P0CM16, P0CM17, P0DH91, P11076, P18085, P19146, P22274, P25160, P26990, P26991, P34212, P34727, P36397, P36404, P36406, P36407, P36579, P38116, P40616, P40617, P40940, P40945, P40946, P40994, P49076, P49702, P51643, P51644, P51645, P51646, P51821, P51822, P51823, P51824, P61204

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

30 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	23
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

263 predictions. Top by Δscore:

Variant	Effect	Δscore
7:12687041:CAG:C	donor_loss	1.0000
7:12687042:AG:A	donor_loss	1.0000
7:12687044:GTG:G	donor_loss	1.0000
7:12687045:T:A	donor_loss	1.0000
7:12688165:GCA:G	acceptor_gain	1.0000
7:12687027:G:T	donor_gain	0.9900
7:12688163:CAGCA:C	acceptor_gain	0.9900
7:12688164:AGCAG:A	acceptor_gain	0.9900
7:12688165:GCAGT:G	acceptor_gain	0.9900
7:12687031:G:GT	donor_gain	0.9800
7:12687039:GTCAG:G	donor_gain	0.9800
7:12688160:TCCCA:T	acceptor_loss	0.9800
7:12688161:CCCA:C	acceptor_loss	0.9800
7:12688162:CCAGC:C	acceptor_loss	0.9800
7:12688163:CA:C	acceptor_loss	0.9800
7:12688164:A:AG	acceptor_gain	0.9800
7:12688165:G:GG	acceptor_gain	0.9800
7:12688167:A:AG	acceptor_gain	0.9800
7:12688168:G:GG	acceptor_gain	0.9800
7:12688168:GTCTT:G	acceptor_gain	0.9800
7:12687027:G:GT	donor_gain	0.9700
7:12688165:GC:G	acceptor_gain	0.9700
7:12687506:G:GT	donor_gain	0.9600
7:12688156:C:A	acceptor_loss	0.9600
7:12688168:GT:G	acceptor_gain	0.9600
7:12688168:GTC:G	acceptor_gain	0.9600
7:12687030:GGACG:G	donor_gain	0.9400
7:12687437:T:TA	donor_gain	0.9400
7:12687438:G:GA	donor_gain	0.9400
7:12688166:CAGTC:C	acceptor_loss	0.9400

AlphaMissense

1297 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
7:12688355:C:T	T34I	1.000
7:12688510:T:A	W86R	1.000
7:12688510:T:C	W86R	1.000
7:12688643:T:C	L130P	1.000
7:12688658:A:T	K135I	1.000
7:12688659:A:C	K135N	1.000
7:12688659:A:T	K135N	1.000
7:12688333:G:C	G27R	0.999
7:12688348:G:A	G32R	0.999
7:12688348:G:C	G32R	0.999
7:12688349:G:A	G32E	0.999
7:12688349:G:T	G32V	0.999
7:12688351:A:C	K33Q	0.999
7:12688353:G:C	K33N	0.999
7:12688353:G:T	K33N	0.999
7:12688414:T:C	F54L	0.999
7:12688416:T:A	F54L	0.999
7:12688416:T:G	F54L	0.999
7:12688477:G:C	D75H	0.999
7:12688478:A:C	D75A	0.999
7:12688478:A:G	D75G	0.999
7:12688502:G:C	R83T	0.999
7:12688503:G:C	R83S	0.999
7:12688503:G:T	R83S	0.999
7:12688512:G:C	W86C	0.999
7:12688512:G:T	W86C	0.999
7:12688537:G:C	G95R	0.999
7:12688538:G:A	G95D	0.999
7:12688550:T:A	V99D	0.999
7:12688555:G:C	D101H	0.999

dbSNP variants (sampled 300 via entrez): RS1000324874 (7:12690015 A>C), RS1001298906 (7:12686843 G>A), RS1001548547 (7:12685775 C>G), RS1002062919 (7:12690732 T>G), RS1002498737 (7:12690444 G>A), RS1002553098 (7:12686823 C>G,T), RS1002606957 (7:12686680 GC>G), RS1003561713 (7:12687650 T>C), RS1003613876 (7:12687466 C>T), RS1004804317 (7:12686993 C>T), RS1006298456 (7:12690911 A>G), RS1006390776 (7:12685158 T>C), RS1006461517 (7:12689320 C>G), RS1007384901 (7:12686579 T>A), RS1007694256 (7:12684925 T>C)

Disease associations

OMIM: gene MIM:604786 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

6 associations (top):

Study	Trait	p-value
GCST002875_54	Diisocyanate-induced asthma	1.000000e-06
GCST007847_97	Type 2 diabetes	3.000000e-09
GCST008053_80	Height	4.000000e-09
GCST008529_41	Tea consumption	2.000000e-07
GCST010276_9	Renal underexcretion gout	3.000000e-07
GCST011742_29	Triglyceride levels in HIV infection	9.000000e-06

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0006995	response to diisocyanate
EFO:0010091	tea consumption measurement
EFO:0004530	triglyceride measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

42 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	affects methylation, decreases expression, increases abundance	4
Cadmium Chloride	increases abundance, increases expression	2
Particulate Matter	decreases expression, increases abundance, affects cotreatment	2
aristolochic acid I	decreases expression	1
dicrotophos	decreases expression	1
bisphenol A	affects cotreatment, increases methylation, decreases methylation	1
methylselenic acid	increases expression	1
methylparaben	decreases expression	1
butyraldehyde	increases expression	1
perfluorooctanoic acid	increases expression	1
S-(1,2-dichlorovinyl)cysteine	decreases expression	1
isobutyl alcohol	affects cotreatment, decreases expression, increases abundance	1
perfluorooctane sulfonic acid	increases expression	1
ICG 001	decreases expression	1
abrine	increases expression	1
jinfukang	decreases expression	1
Temozolomide	increases expression	1
Sunitinib	increases expression	1
Fulvestrant	affects cotreatment, increases methylation	1
Leflunomide	affects expression	1
Air Pollutants	decreases expression, increases abundance	1
Air Pollutants, Occupational	increases expression	1
Ethanol	decreases expression, increases abundance, affects cotreatment	1
Arsenic	decreases expression, increases abundance	1
Vehicle Emissions	decreases methylation	1
Benzo(a)pyrene	increases methylation	1
Cadmium	increases abundance, increases expression	1
Calcitriol	decreases expression	1
Estradiol	decreases expression	1
Gasoline	affects cotreatment, decreases expression, increases abundance	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.